Temozolomide is an active agent in children with recurrent medulloblastoma/primitive neuroectodermal tumor: an Italian multi-institutional phase II trial

Antonio Ruggiero, Cesare Colosimo, Giuseppe Barone, Vita Ridola, Riccardo Riccardi, Graziella Cefalo, Maura Massimino, Filippo Spreafico, Paolo Potepan, Massimo E. Abate, Maurizio Mascarin, Maria Luisa Garrè, Giorgio Perilongo, Enrico Madon

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

The aim of this study was to assess the objective response rate (ORR) of children and young adults with recurrent medulloblastoma/primitive neuroectodermal tumor (MB/PNET) treated with temozolomide (TMZ). The secondary purpose was to analyze the toxicity profile of TMZ when administered orally for 5 days in 3 divided daily doses every 28 days.
Original languageEnglish
Pages (from-to)748-753
Number of pages6
JournalNeuro-Oncology
Volume16
DOIs
Publication statusPublished - 2014

Keywords

  • medulloblastoma
  • phase II trial
  • temozolomide

Fingerprint

Dive into the research topics of 'Temozolomide is an active agent in children with recurrent medulloblastoma/primitive neuroectodermal tumor: an Italian multi-institutional phase II trial'. Together they form a unique fingerprint.

Cite this